First time human-on-a-chip predicts in vivo results based on in vitro model

(Bioscribe) In a study published in Nature Scientific Reports, in collaboration with AstraZeneca, Hesperos described how they used a pumpless heart model and a heart:liver system to evaluate the temporal pharmacokinetic/pharmacodynamic relationship for terfenadine, an antihistamine that was banned due to toxic cardiac effects, as well as determine its mechanism of toxicity. The findings further support the potential of body-on-a-chip systems to transform the drug discovery process and prevent needless time consuming and costly animal studies.

from EurekAlert! - Social and Behavioral Science https://ift.tt/2KUuUK7